COMPREHENSIVE REVIEW ON NANOCRYSTAL TECHNOLOGY IN PHARMACEUTICAL FORMULATIONS

MANOJKUMAR K. MUNDE; ANKITA M. SHINDE; NILESH S. KULKARNI; VRUSHALI S. TAMBE; HEMANT P. ALHAT

doi:10.22159/ijpps.2023v15i4.47317

Authors

MANOJKUMAR K. MUNDE PES Modern College of Pharmacy (for Ladies), Affiliated to Savitribai Phule Pune University, Moshi, Pune 412105, Maharashtra, India https://orcid.org/0000-0002-9484-5690
ANKITA M. SHINDE PES Modern College of Pharmacy (for Ladies), Affiliated to Savitribai Phule Pune University, Moshi, Pune 412105, Maharashtra, India https://orcid.org/0009-0001-7448-4138
NILESH S. KULKARNI PES Modern College of Pharmacy (for Ladies), Affiliated to Savitribai Phule Pune University, Moshi, Pune 412105, Maharashtra, India https://orcid.org/0000-0002-4801-9419
VRUSHALI S. TAMBE PES Modern College of Pharmacy (for Ladies), Affiliated to Savitribai Phule Pune University, Moshi, Pune 412105, Maharashtra, India https://orcid.org/0000-0002-5779-3035
HEMANT P. ALHAT PES Modern College of Pharmacy (for Ladies), Affiliated to Savitribai Phule Pune University, Moshi, Pune 412105, Maharashtra, India

DOI:

https://doi.org/10.22159/ijpps.2023v15i4.47317

Keywords:

Nanocrystal, Bottom-up, Top-down, Poor solubility, Bioavailability

Abstract

Many techniques have been developed to overcome the bioavailability problem of poorly soluble drugs. The nanonization is one of the techniques in that micronized particle is converted in nanoparticle. Several processes are applied for nanocrystal production, including precipitation, milling, high pressure homogenization and combination method. The nanocrystal formulation is administered via various routes like oral, intravenous, intramuscular, pulmonary, ocular and dermal but due to safety, patient compliance and ease of administration, oral drug delivery is preferred. There are two basic ways to prepare drug nanocrystals like “bottom-up” and “top-down” technologies. The present literature provides an overview of the achievement in improving the bioavailability of the poorly soluble drug by using different methods.

Downloads

Download data is not yet available.

References

Kipp JE. The role of solid nanoparticle technology in the parenteral delivery of poorly water-soluble drugs. Int J Pharm. 2004 Oct 13;284(1-2):109-22. doi: 10.1016/j.ijpharm.2004.07.019. PMID 15454302.

Irache JM, Esparza I, Gamazo C, Agueros M, Espuelas S. Nanomedicine: novel approaches in human and veterinary therapeutics. Vet Parasitol. 2011 Aug 4;180(1-2):47-71. doi: 10.1016/j.vetpar.2011.05.028. PMID 21680101.

Chen H, Khemtong C, Yang X, Chang X, Gao J. Nanonization strategies for poorly water-soluble drugs. Drug Discov Today. 2011 Apr;16(7-8):354-60. doi: 10.1016/j.drudis.2010.02.009. PMID 20206289.

Ahuja BK, Jena SK, Paidi SK, Bagri S, Suresh S. Formulation, optimization and in vitro-in vivo evaluation of febuxostat nanosuspension. Int J Pharm. 2015 Jan 30;478(2):540-52. doi: 10.1016/j.ijpharm.2014.12.003. PMID 25490182.

Saini JK, Kumar S. Development of nanocrystal formulation with improved dissolution. J Drug Delivery Ther. 2018 Sep 9;8(5):118-29. doi: 10.22270/jddt.v8i5.1946.

Gao L, Liu G, Ma J, Wang X, Wang F, Wang H. Paclitaxel nanosuspension coated with P-gp inhibitory surfactants: II. Ability to reverse the drug resistance of H460 human lung cancer cells. Colloids Surf B Biointerfaces. 2014 May 1;117:122-7. doi: 10.1016/j.colsurfb.2014.02.016. PMID 24632038.

Gao L, Liu G, Ma J, Wang X, Zhou L, Li X. Application of drug nanocrystal technologies on oral drug delivery of poorly soluble drugs. Pharm Res. 2013 Feb;30(2):307-24. doi: 10.1007/s11095-012-0889-z. PMID 23073665.

Junghanns JU, Muller RH. Nanocrystal technology, drug delivery and clinical applications. Int J Nanomedicine. 2008;3(3):295-309. doi: 10.2147/ijn.s595. PMID 18990939, PMCID PMC2626933.

Tuomela A, Hirvonen J, Peltonen L. Stabilizing agents for drug nanocrystals: effect on bioavailability. Pharmaceutics. 2016 May 20;8(2):16. doi: 10.3390/pharmaceutics8020016, PMID 27213435, PMCID PMC4932479.

Mah PT, Laaksonen T, Rades T, Peltonen L, Strachan CJ. Differential scanning calorimetry predicts the critical quality attributes of amorphous glibenclamide. Eur J Pharm Sci. 2015 Dec 1;80:74-81. doi: 10.1016/j.ejps.2015.08.006. PMID 26296864.

Zhao R, Hollis CP, Zhang H, Sun L, Gemeinhart RA, Li T. Hybrid nanocrystals: achieving concurrent therapeutic and bioimaging functionalities toward solid tumors. Mol Pharm. 2011 Oct 3;8(5):1985-91. doi: 10.1021/mp200154k. PMID 21812439.

Hancock BC, Parks M. What is the true solubility advantage for amorphous pharmaceuticals? Pharm Res. 2000 Apr;17(4):397-404. doi: 10.1023/a:1007516718048. PMID 10870982.

Junghanns JU, Muller RH. Nanocrystal technology, drug delivery and clinical applications. Int J Nanomedicine. 2008;3(3):295-309. doi: 10.2147/ijn.s595. PMID 18990939, PMCID PMC2626933.

Rogers Hayden T, Pidgeon N. Moving engagement ”upstream”? Nanotechnologies and the royal society and royal academy of engineering’s inquiry. Public Underst Sci. 2007 Jul;16(3):345-64. doi: 10.1177/0963662506076141.

Lovestam G, Rauscher H, Roebben G, Kluttgen BS, Gibson N, Putaud JP. Considerations on a definition of nanomaterial for regulatory purposes. Joint Research Centre (JRC) Reference Reports. 2010 Aug 25;80:1-41.

Muller RH, Gohla S, Keck CM. State of the art of nanocrystals--special features, production, nanotoxicology aspects and intracellular delivery. Eur J Pharm Biopharm. 2011 May;78(1):1-9. doi: 10.1016/j.ejpb.2011.01.007. PMID 21266197.

Liu P, Rong X, Laru J, van Veen B, Kiesvaara J, Hirvonen J. Nanosuspensions of poorly soluble drugs: preparation and development by wet milling. Int J Pharm. 2011 Jun 15;411(1-2):215-22. doi: 10.1016/j.ijpharm.2011.03.050. PMID 21458552.

Shegokar R, Muller RH. Nanocrystals: industrially feasible multifunctional formulation technology for poorly soluble actives. Int J Pharm. 2010 Oct 31;399(1-2):129-39. doi: 10.1016/j.ijpharm.2010.07.044. PMID 20674732.

Shegokar R, Singh KK. Surface modified nevirapine nanosuspensions for viral reservoir targeting: in vitro and in vivo evaluation. Int J Pharm. 2011 Dec 15;421(2):341-52. doi: 10.1016/j.ijpharm.2011.09.041, PMID 21986114.

Chen L, Wang Y, Zhang J, Hao L, Guo H, Lou H. Bexarotene nanocrystal-oral and parenteral formulation development, characterization and pharmacokinetic evaluation. Eur J Pharm Biopharm. 2014 May;87(1):160-9. doi: 10.1016/j.ejpb.2013.12.005. PMID 24333772.

Chen ML, John M, Lee SL, Tyner KM. Development considerations for nanocrystal drug products. AAPS J. 2017 May;19(3):642-51. doi: 10.1208/s12248-017-0064-x, PMID 28281194.

Mitri K, Shegokar R, Gohla S, Anselmi C, Muller RH. Lutein nanocrystals as an antioxidant formulation for oral and dermal delivery. Int J Pharm. 2011 Nov 25;420(1):141-6. doi: 10.1016/j.ijpharm.2011.08.026, PMID 21884768.

Sun J, Wang F, Sui Y, She Z, Zhai W, Wang C. Effect of particle size on solubility, dissolution rate, and oral bioavailability: evaluation using coenzyme Q₁₀ as naked nanocrystals. Int J Nanomedicine. 2012;7:5733-44. doi: 10.2147/IJN.S34365. PMID 23166438, PMCID PMC3500035.

Fu Q, Sun J, Ai X, Zhang P, Li M, Wang Y. Nimodipine nanocrystals for oral bioavailability improvement: role of mesenteric lymph transport in the oral absorption. Int J Pharm. 2013 May;448(1):290-7. doi: 10.1016/j.ijpharm.2013.01.065. PMID 23384726.

Ige PP, Baria RK, Gattani SG. Fabrication of fenofibrate nanocrystals by probe sonication method for enhancement of dissolution rate and oral bioavailability. Colloids Surf B Biointerfaces. 2013 Aug 1;108:366-73. doi: 10.1016/j.colsurfb.2013.02.043. PMID 23602990.

Chen L, Wang Y, Zhang J, Hao L, Guo H, Lou H. Bexarotene nanocrystal-oral and parenteral formulation development, characterization and pharmacokinetic evaluation. Eur J Pharm Biopharm. 2014 May;87(1):160-9. doi: 10.1016/j.ejpb.2013.12.005. PMID 24333772.

Fu Q, Sun J, Zhang D, Li M, Wang Y, Ling G. Nimodipine nanocrystals for oral bioavailability improvement: preparation, characterization and pharmacokinetic studies. Colloids Surf B Biointerfaces. 2013 Sep 1;109:161-6. doi: 10.1016/j.colsurfb.2013.01.066. PMID 23668980.

Shegokar R, Muller RH. Nanocrystals: industrially feasible multifunctional formulation technology for poorly soluble actives. Int J Pharm. 2010 Oct 31;399(1-2):129-39. doi: 10.1016/j.ijpharm.2010.07.044. PMID 20674732.

Rao YM, Kumar MP, Apte S. Formulation of nanosuspensions of albendazole for oral administration. Curr Nanosci. 2008 Feb 1;4(1):53-8. doi: 10.2174/157341308783591807.

Liu P, Rong X, Laru J, van Veen B, Kiesvaara J, Hirvonen J. Nanosuspensions of poorly soluble drugs: preparation and development by wet milling. Int J Pharm. 2011 Jun 15;411(1-2):215-22. doi: 10.1016/j.ijpharm.2011.03.050. PMID 21458552.

Gigliobianco MR, Casadidio C, Censi R, Di Martino P. Nanocrystals of poorly soluble drugs: drug bioavailability and physicochemical stability. Pharmaceutics. 2018 Aug 21;10(3):134. doi: 10.3390/pharmaceutics10030134, PMID 30134537.

Pi J, Wang S, Li W, Kebebe D, Zhang Y, Zhang B. A nano-cocrystal strategy to improve the dissolution rate and oral bioavailability of baicalein. Asian J Pharm Sci. 2019 Mar;14(2):154-64. doi: 10.1016/j.ajps.2018.04.009. PMID 32104447, PMCID PMC7032205.

Kumar S, Kamath K, Shabaraya AR. Nanocrystals: a novel approach in the delivery of hydrophobic drugs; 2014.

Xiong S, Liu W, Zhou Y, Mo Y, Liu Y, Chen X. Enhancement of oral bioavailability and anti-parkinsonian efficacy of resveratrol through a nanocrystal formulation. Asian J Pharm Sci. 2020 Jul;15(4):518-28. doi: 10.1016/j.ajps.2019.04.003. PMID 32952674, PMCID PMC7486547.

COMPREHENSIVE REVIEW ON NANOCRYSTAL TECHNOLOGY IN PHARMACEUTICAL FORMULATIONS

Authors

DOI:

Keywords:

Abstract

Downloads

References

Published

How to Cite

Issue

Section